Single Versus Maintenance Intravesical Chemotherapy for the Prevention of Bladder Recurrence after Radical Nephroureterectomy for Upper Tract Urothelial Carcinoma: A Randomized Clinical Trial

被引:22
作者
Harraz, Ahmed M. [1 ]
El-Shabrawy, Magdy [1 ]
El-Nahas, Ahmed R. [1 ]
El-Kappany, Hamdy [1 ]
Osman, Yasser [1 ]
机构
[1] Mansoura Univ, Urol & Nephrol Ctr, Mansoura, Egypt
关键词
Maintenance therapy; Urothelial carcinoma; BLadder Recurrence; Nephroureterectomy; BLOOD-TRANSFUSION; MITOMYCIN-C; INSTILLATION; TUMORS; SURVIVAL; SURGERY; RISK; ASSOCIATION; MULTICENTER; PIRARUBICIN;
D O I
10.1016/j.clgc.2019.07.019
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Bladder recurrence (BR) after radical nephroureterectomy is a significant problem that might be a result of field change or tumor seeding theories. Like non-emuscle-invasive bladder cancer, maintenance intravesical chemotherapy is thought to decrease BR when compared with single instillations. Nevertheless, we found a comparable incidence of BR in both groups through a randomized clinical trial. Furthermore, the presence of lymphovascular invasion was found to be an independent predictor of BR. Introduction: The objective of this study was to determine the efficiency of 1-year maintenance intravesical chemotherapy (MIC) in reducing bladder recurrence (BR) after radical nephroureterectomy (RNU) for upper tract urothelial carcinoma compared with single intravesical instillation (SIC). Patients and Methods: Between January 2015 and May 2017, patients who underwent RNU were randomized to receive SIC (epirubicin 50 mg) or MIC (once weekly for 6 weeks plus once monthly for 1 year). The primary outcome was the rate of histologically proven BR. The secondary outcomes included chemotherapy-related toxicities and disease-specific survival (DSS). Thirty-five patients in each arm were required to achieve a power of 80%. Results: A total of 38 (SIC) and 36 (MIC) patients were analyzed. In SIC, BR developed in 5 (13.2%) over a median follow-up of 3 months (range, 3-6 months) compared with 9 (25%) patients over 12 months (range, 3-28 months) in MIC (P = .08). The 6- and 12-month BR-free survivals were the same (86.8%) in SIC versus 88.9% and 83.3% in MIC, respectively (P = .2). Lymphovascular invasion was significantly associated with BR (P = .04). Post-RNU intravesical chemotherapy regimens did not alter DSS. Blood transfusion and advanced tumor stage were independent predictors for DSS. No significant medication toxicity was reported. Conclusions: Following RNU, MIC did not change the natural course of BR beyond a single instillation apart from potentially delaying its occurrence. Lymphovascular invasion and blood transfusion were associated with worse BR and DSS outcomes, respectively.
引用
收藏
页码:E1108 / E1115
页数:8
相关论文
共 30 条
[1]   Classification of surgical complications - A new proposal with evaluation in a cohort of 6336 patients and results of a survey [J].
Dindo, D ;
Demartines, N ;
Clavien, PA .
ANNALS OF SURGERY, 2004, 240 (02) :205-213
[2]  
Elawdy MM, 2017, ARAB J UROL, V15, P216, DOI 10.1016/j.aju.2017.03.006
[3]   Prophylactic Intravesical Chemotherapy to Prevent Bladder Tumors after Nephroureterectomy for Primary Upper Urinary Tract Urothelial Carcinomas: A Systematic Review and Meta-Analysis [J].
Fang, Dong ;
Li, Xue-Song ;
Xiong, Geng-Yan ;
Yao, Lin ;
He, Zhi-Song ;
Zhou, Li-Qun .
UROLOGIA INTERNATIONALIS, 2013, 91 (03) :291-296
[4]   G*Power 3: A flexible statistical power analysis program for the social, behavioral, and biomedical sciences [J].
Faul, Franz ;
Erdfelder, Edgar ;
Lang, Albert-Georg ;
Buchner, Axel .
BEHAVIOR RESEARCH METHODS, 2007, 39 (02) :175-191
[5]  
Gupta Sandeep K, 2011, Perspect Clin Res, V2, P109, DOI 10.4103/2229-3485.83221
[6]   Clonality of multifocal urothelial carcinomas: 10 years of molecular genetic studies [J].
Hafner, C ;
Knuechel, R ;
Stoehr, R ;
Hartmann, A .
INTERNATIONAL JOURNAL OF CANCER, 2002, 101 (01) :1-6
[7]   BLADDER-CANCER - FIELD VERSUS CLONAL ORIGIN [J].
HARRIS, AL ;
NEAL, DE .
NEW ENGLAND JOURNAL OF MEDICINE, 1992, 326 (11) :759-761
[8]  
Huncharek M, 2001, ANTICANCER RES, V21, P765
[9]   Intravesical Seeding of Upper Urinary Tract Urothelial Carcinoma Cells During Nephroureterectomy: An Exploratory Analysis from the THPMG Trial [J].
Ito, Akihiro ;
Shintaku, Ichiro ;
Satoh, Makoto ;
Ioritani, Naomasa ;
Tochigi, Tatsuo ;
Numata, Isao ;
Namima, Takashige ;
Kambe, Koichi ;
Kyan, Atsushi ;
Ueno, Seiji ;
Katoh, Shinnosuke ;
Adachi, Hisanobu ;
Yamashita, Shinichi ;
Yamaguchi, Takuhiro ;
Arai, Yoichi .
JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2013, 43 (11) :1139-1144
[10]   Prospective Randomized Phase II Trial of a Single Early Intravesical Instillation of Pirarubicin (THP) in the Prevention of Bladder Recurrence After Nephroureterectomy for Upper Urinary Tract Urothelial Carcinoma: The THP Monotherapy Study Group Trial [J].
Ito, Akihiro ;
Shintaku, Ichiro ;
Satoh, Makoto ;
Ioritani, Naomasa ;
Aizawa, Masataka ;
Tochigi, Tatsuo ;
Kawamura, Sadafumi ;
Aoki, Hiroshi ;
Numata, Isao ;
Takeda, Atsushi ;
Namiki, Shunichi ;
Namima, Takashige ;
Ikeda, Yoshihiro ;
Kambe, Koichi ;
Kyan, Atsushi ;
Ueno, Seiji ;
Orikasa, Kazuhiko ;
Katoh, Shinnosuke ;
Adachi, Hisanobu ;
Tokuyama, Satoru ;
Ishidoya, Shigeto ;
Yamaguchi, Takuhiro ;
Arai, Yoichi .
JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (11) :1422-1427